Skip to main content

Table 3 Model input parameters and their uncertainty distributions

From: Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study

Parameter    Value
Mean (SE or 95%CI)
Uncertainty distribution Sources and assumptions
RR of IHD with treatment    
-Statin
-Diuretic
-Calcium channel blocker
-ACE inhibitor
-Beta-blocker
0.70 (0.61 to 0.81)
0.86 (0.75 to 0.98)
0.85 (0.78 to 0.92)
0.83 (0.78 to 0.89)
0.78 (0.89 to 1.02)
Normal (lnRR) Meta-analyses of primary prevention trials [5, 6, 47]
RR of stroke with treatment    
-Statin
-Diuretic
-Calcium channel blocker
-ACE inhibitor
-Beta-blocker
0.81 (0.71 to 0.93)
0.62 (0.53 to 0.72)
0.66 (0.58 to 0.75)
0.78 (0.66 to 0.92)
0.70 (0.83 to 0.99)
Normal (lnRR) Meta-analyses of primary prevention trials [5, 6, 47]
RR of stroke in IHD    
-Men
-Women
1.32 (0.20)
1.88 (0.30)
Normal (lnRR) Busselton study [48, 49]
RR of IHD in stroke    
-Men
-Women
2.64 (0.07)
2.85 (0.04)
Normal (lnRR) Busselton study [48, 49]
IHD treatment cost    
-First year
-Subsequent years
$12,921
$4,539
Uniform Lim [43]. Uniform distribution assumed to vary by ±25% around mean.
Stroke treatment cost    
-First year
-Subsequent years
$23,581
$3,201
Uniform Lim [43]. Uniform distribution assumed to vary by ±25% around mean.
Proportion of population visiting a GP in one year    
35–44 yrs
45–54 yrs
55–64 yrs
65–74 yrs
75+ yrs
Men Women
73% 88%
81% 89%
81% 89%
93% 94%
99% 99%
BEACH data [17]
Proportion of GPs measuring absolute risk 65% (6.5%) Beta Practice Incentives Program data [50].
First year drug discontinuation rate 40% (8%) Beta Estimate from Australian survey data [21, 22]. Standard error assumed to be 20% of point estimate.
  1. NB. All costs adjusted to 2008 Australian dollars using Australian health price deflators [39]. RR – relative risk.